Ultragenyx Pharmaceutical Inc. filings document a rare-disease biopharmaceutical business with approved medicines, investigational genetic-disease therapies, and a Nasdaq-listed common stock capital structure. Form 8-K reports include operating results, financial guidance, FDA communications, clinical-study data, and risk language tied to drug development, regulatory review, manufacturing, funding needs, competition, and commercialization.
Proxy materials describe annual-meeting matters, board and compensation governance, equity compensation, and stockholder voting. Recent current reports also record restructuring and cost disclosures, employment-related equity plans, and material updates for programs including UX111, UX016, DTX301, DTX401, and GTX-102.
Ultragenyx Pharmaceutical Inc. EVP and Chief Legal Officer Karah Herdman Parschauer reported a sale of 1,900 shares of common stock on August 3, 2026 at $24.92 per share under a Rule 10b5-1 trading plan. Following this transaction, she directly holds 92,562 shares, including previously reported RSU-based shares subject to vesting conditions.
Ultragenyx Pharmaceutical Inc. reports that Chief Financial Officer Howard Horn sold 4,696 shares of common stock on August 3, 2026 at $24.92 per share in an open-market or private transaction under a Rule 10b5-1 trading plan, and now directly holds 96,295 shares, including shares underlying RSUs that remain subject to vesting conditions.
Ultragenyx Pharmaceutical Inc. (RARE) has a planned sale of restricted securities reported by Howard Horn under a notice of proposed sale of securities. The filing lists up to 4,696 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $117,024.32 and CUSIP 98489224, on the NASDAQ market. These shares were acquired as Restricted Stock and Performance Shares dated March 1, 2025.
The filing also lists securities sold during the past three months by Howard Horn: 4,698 common shares sold on July 1, 2026 for $155,644.74, and 4,653 common shares sold on June 1, 2026 for $110,601.81.
Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of 6,853,427 shares of Ultragenyx Pharmaceutical Inc. common stock on an amended Schedule 13G as of June 30, 2026. This represents 6.95% of the outstanding class.
Vanguard has sole voting power over 63,292 shares and sole dispositive power over all 6,853,427 shares, with no shared voting or dispositive power. The reported holdings include securities held by Vanguard funds and managed accounts over which the reporting business units exercise voting and/or dispositive authority, but exclude positions held by other Vanguard affiliates whose ownership is disaggregated. Vanguard notes that its investment companies and other managed accounts have the right to receive dividends and sale proceeds from these securities, and that no other single person’s interest in the reported securities exceeds 5% of the class.
Vanguard Capital Management reports beneficial ownership of 5,058,419 shares of Ultragenyx Pharmaceutical Inc. common stock on a Schedule 13G. This represents 5.13% of the outstanding common stock.
Vanguard has sole power to vote 761,928 shares and sole power to dispose of 5,058,419 shares, with no shared voting or dispositive power. The filing aggregates holdings of Vanguard Capital Management LLC and certain affiliates and Vanguard funds over which they exercise dispositive and/or voting power. Vanguard entities and managed accounts have the right to receive dividends and sale proceeds from these securities, and no other single person’s interest exceeds 5% of the class.
BlackRock, Inc. has filed an amended Schedule 13G reporting its beneficial ownership of common stock of Ultragenyx Pharmaceutical Inc. BlackRock reports beneficial ownership of 8,141,384 shares, representing 8.3% of Ultragenyx’s outstanding common stock.
BlackRock has sole voting power over 7,991,763 shares and sole dispositive power over all 8,141,384 shares, with no shared voting or dispositive power. Various underlying clients and accounts have rights to dividends and sale proceeds, but no single person holds more than five percent of Ultragenyx’s outstanding common shares through these interests.
Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported an open-market sale of 4,698 shares of common stock at a price of $33.13 per share. After this transaction, he directly owns 100,991 shares. His reported holdings include shares underlying previously granted RSUs that vest over time.
RARE affiliate disclosed proposed and recent resales of Common Stock on a Form 144. The filing lists scheduled issuances of Restricted Stock and Performance Shares with grant dates and quantities, and records two recent open-market sales by Howard Horn of 4,653 shares on 06/01/2026 for $110,601.81 and 4,683 shares on 05/01/2026 for $116,606.70.
Ultragenyx Pharmaceutical Inc. director Sanders Corazon (Corsee) D. sold 2,000 shares of Common Stock in an open-market transaction at $25.05 per share. After this sale, the director directly holds 21,095 shares. The reported holdings include previously disclosed RSUs that will vest over time.
Ultragenyx Pharmaceutical Inc. executive Karah Herdman Parschauer reported an open-market sale of 1,899 shares of common stock at $24.62 per share. After this transaction, she directly holds 94,462 shares. Her holdings include 646 shares acquired under the company’s Employee Stock Purchase Plan and previously reported RSU-based common stock that remains subject to vesting conditions.